celares GmbH is a German CDMO focused on the development and manufacturing of polymer-based drug delivery excipients and bioconjugate drugs. The company specializes in PEGylation technology and conjugate vaccine development, with collaborations including EMD Millipore and NOF Corporation. celares has been acquired by Biosynth, which expanded its capabilities into conjugate vaccines and bioconjugation services.
PEGylation, bioconjugation, polymer-based drug delivery, conjugate vaccines, bioconjugate drug manufacturing
1 site worldwide
No reviews available yet.
No documents available.